← Qiagen NV overview

Qiagen NV vs Illumina: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Qiagen NV (QGEN)

Q3 2026
▲3▼1

Qiagen Draws Buyout Interest, Wins FDA Clearance, But Patent Loss Weighs

  • Takeover interest at $50/share Private equity firms EQT, Advent, and KKR expressed interest in buying Qiagen for about $50 per share, well above its ~$41.50 price. Two entered formal due diligence, though they could still walk away.

    This is the biggest new event that could drive the stock price higher.

  • FDA clearance for sepsis panel Qiagen won FDA clearance for its QIAstat-Dx bloodstream infection panel, opening the U.S. sepsis testing market. It also launched the QIAmini system and AI bioinformatics tools.

    New product approvals and launches can boost future sales and investor confidence.

  • Q2 results beat and guidance reaffirmed Qiagen's second-quarter results beat its own guidance, and the company reaffirmed its outlook. This shows the core business is performing well despite the takeover talks.

    Strong financial performance supports the stock price and validates the business.

  • Patent loss and CEO uncertainty A jury ordered subsidiary Parse Biosciences to pay $4.8 million for patent infringement, with injunction and enhanced damages sought. Meanwhile, new CEO Jonathan Pratt takes over during sale talks, adding uncertainty.

    These risks could disrupt operations and weigh on the stock, providing a counterweight to positive news.

August 2026
▲3▼1

Qiagen Draws Buyout Interest, Wins FDA Clearance, But Patent Loss Weighs

  • Takeover interest at $50/share Private equity firms EQT, Advent, and KKR expressed interest in buying Qiagen for about $50 per share, well above its ~$41.50 price. Two entered formal due diligence, though they could still walk away.

    This is the biggest new event that could drive the stock price higher.

  • FDA clearance for sepsis panel Qiagen won FDA clearance for its QIAstat-Dx bloodstream infection panel, opening the U.S. sepsis testing market. It also launched the QIAmini system and AI bioinformatics tools.

    New product approvals and launches can boost future sales and investor confidence.

  • Q2 results beat and guidance reaffirmed Qiagen's second-quarter results beat its own guidance, and the company reaffirmed its outlook. This shows the core business is performing well despite the takeover talks.

    Strong financial performance supports the stock price and validates the business.

  • Patent loss and CEO uncertainty A jury ordered subsidiary Parse Biosciences to pay $4.8 million for patent infringement, with injunction and enhanced damages sought. Meanwhile, new CEO Jonathan Pratt takes over during sale talks, adding uncertainty.

    These risks could disrupt operations and weigh on the stock, providing a counterweight to positive news.

Latest
▲3▼1

Qiagen's product launches and FDA clearances drive growth, offset by patent loss

  • New product launches expand addressable market Qiagen launched several new products: a bloodstream infection test panel in Europe, the QIAmini benchtop system for small labs, and AI bioinformatics tools. These launches open new revenue streams and strengthen Qiagen's competitive position, supporting future sales growth.

    These launches are new events that directly expand Qiagen's product portfolio and potential revenue.

  • FDA clearances open U.S. market for sepsis testing Qiagen received FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, giving U.S. labs access to a complete rapid sepsis testing portfolio. This regulatory win allows Qiagen to sell these tests in the U.S., a large market, driving future revenue.

    FDA clearances are new regulatory milestones that enable U.S. sales and validate Qiagen's technology.

  • Patent dispute leads to $4.8M damages and injunction risk A jury ordered Qiagen's subsidiary Parse Biosciences to pay $4.8 million for infringing patents, and the plaintiff seeks an injunction and enhanced damages. This legal setback could disrupt Parse's operations and add costs, weighing on Qiagen's stock.

    The patent loss is a new negative event with potential financial and operational impact.

  • Q2 earnings beat and guidance reaffirmed Qiagen reported Q2 sales and earnings above its outlook, with growth pillars like Sample technologies and QIAcuity performing well. The company reaffirmed full-year guidance, signaling stability and resilience despite currency headwinds.

    The earnings beat is a new positive financial update that reassures investors about Qiagen's performance.

▲3

Qiagen takeover interest firms up as FDA clears new test

  • Takeover interest at $50+ per share Private equity firms including EQT, Advent and KKR are exploring a buyout of Qiagen at around $50 a share, well above its recent price near $41.50. A takeover at that level would hand shareholders a large premium, so the stock jumped on the news.

    This is the main force behind Qiagen's move and the core of the period's news.

  • Formal due diligence begins with two buyers Two potential buyers have started formal due diligence on Qiagen, with a sale price around $50 a share being discussed. This shows the takeover talks are progressing beyond early interest, which supports the stock, though the buyers could still walk away and Qiagen could stay independent.

    It is a new, concrete step that advances the takeover story and affects the price.

  • First FDA clearance for bloodstream infection panel Qiagen won FDA clearance for its QIAstat-Dx bloodstream infection panel, letting it enter the U.S. market for rapid sepsis testing. This opens a new revenue stream and supports future growth, giving fundamental backing to the stock beyond takeover talk.

    It is a new product milestone that adds real business value and supports the share price.

  • New CEO named amid takeover talks Qiagen appointed Jonathan Pratt as CEO from September 1, succeeding Thierry Bernard, while takeover discussions continue. A leadership change during a sale process adds uncertainty, but the company reaffirmed its 2026 outlook, so the effect on the stock is mixed.

    It is a new event that could sway investor confidence and the takeover outcome.

Illumina Inc (ILMN)

Q3 2026
▲2▼1

Illumina Surges on Earnings Beat, S&P 500 Entry, Biotech Boom

  • Earnings Beat and Raised Guidance Illumina beat earnings and raised guidance, with revenue up 4.8% to $1.09 billion. Clinical sequencing demand stayed strong, growing 20% outside China, and NovaSeq X placements topped 80 units.

    This point explains the fundamental business strength that drove the stock higher.

  • S&P 500 Inclusion and Biotech Boom The stock gained 46% amid a biotech boom, and Illumina joined the S&P 500, attracting index-fund demand. Eli Lilly joined its Billion Cell Atlas, and Merck/Moderna's cancer vaccine success boosted shares 15.6%.

    This point captures the market and partnership catalysts that amplified the stock's rise.

  • Roche Launches Cheaper Competing Sequencer Roche launched a competing sequencer at $750,000, well below Illumina's $985,000–$1.25 million, threatening its ~70% market share and potentially forcing price cuts or slower sales. Analysts expect gradual share erosion rather than collapse.

    This point highlights the main competitive threat that could pressure future growth.

August 2026
▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

  • Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.

    This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.

  • Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.

    It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.

  • Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.

    It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.

  • Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.

    It is a new capital-markets event that mechanically increases demand for ILMN shares.

Latest
▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

  • Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.

    This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.

  • Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.

    It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.

  • Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.

    It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.

  • Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.

    It is a new capital-markets event that mechanically increases demand for ILMN shares.

July 2026
▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

  • Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.

    This is the biggest new positive event this period and directly explains the stock's jump.

  • Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.

    This is a new competitive threat that directly pressures Illumina's pricing and market dominance.

  • Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.

    This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.

  • Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.

    This explains the sector-wide force behind Illumina's rally, giving the big-picture context.

▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

  • Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.

    This is the biggest new positive event this period and directly explains the stock's jump.

  • Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.

    This is a new competitive threat that directly pressures Illumina's pricing and market dominance.

  • Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.

    This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.

  • Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.

    This explains the sector-wide force behind Illumina's rally, giving the big-picture context.